从中国疫情最严重时就在提康复者血清的问题，此前还咨询过免疫和急诊的专家，对康复者血清均持比较谨慎的态度，另外也看血清抗体的纯化程度。3月27日JAMA上刊登了南方科技大学与深圳第三人民医院使用康复者的血清治疗了5名发生呼吸窘迫综合征的新冠肺炎患者的研究结果，说实话感觉如果不是COVID-19，这样的研究不会刊登在JAMA上吧。之后看到同期关于该项康复者血清治疗研究的述评，看起来这篇述评更有意义，貌似前些天看来关注述评内容的人不多，所以再发一下了（好在是free）。
大段文字懒得拷了，附一个原文链接：https://jamanetwork.com/journals/jama/fullarticle/2763982
最后一段可以看一下，尤其是在目前国内疫情基本得到控制，还有大量康复者的情况下：
Both academic and industry groups are beginning to investigate the efficacy of passive antibody therapies for COVID-19 infection. If substantial, robust evidence from rigorously conducted clinical trials clearly establishes effectiveness, and if tests could identify patients who could benefit from passive immunity, the US and other countries could consider a national campaign to provide such treatment. Although a logistical challenge, this may be one approach to protect high-risk populations and could synergize with parallel efforts to develop vaccines and antiviral drugs. However, just as executive direction was critical for rapid implementation of COVID-19 tests, so it will be important to accelerate this effort. Specifically, guidance would be needed to direct blood centers and plasma fractionators to begin prioritizing collections from COVID-19-convalescent donors; expedite the availability of these products for therapeutic use; create a data collection, analysis, and regulatory infrastructure to identify factors that predict therapeutic efficacy and to inform the relative levels of convalescent plasma vs H-Ig production; and remove regulatory barriers that, for example, currently limit the use of pathogen reduction technology for convalescent plasma collections or that require several-month inventory holds on H-Ig pharmaceuticals.